Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma
- 1 May 2007
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 73 (9), 1308-1317
- https://doi.org/10.1016/j.bcp.2006.12.031
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- CholangiocarcinomaThe Lancet, 2005
- Raf: A Strategic Target for Therapeutic Development Against CancerJournal of Clinical Oncology, 2005
- Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control studyGastroenterology, 2005
- The ERK Cascade: A Prototype of MAPK SignalingMolecular Biotechnology, 2005
- The Epidemiology of CholangiocarcinomaSeminars in Liver Disease, 2004
- Changing international trends in mortality rates for liver, biliary and pancreatic tumoursJournal of Hepatology, 2002
- Pharmacological inhibitors of MAPK pathwaysTrends in Pharmacological Sciences, 2002
- Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United StatesHepatology, 2001
- Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998Gut, 2001
- Recent Advances in the Management of CholangiocarcinomasSeminars in Liver Disease, 1994